Member Info for Acuere

Apparently updated broker note today (I assume Fincap) has short term target price of 150p.
Obviously FDA approval would see that raised somewhat.

LittleWing,
If you view a year as a long time in investing, I don’t think Maxcyte is the share for you as the real rewards will come over a 5 year plus timescale.

Here is a view from Modelio Equity re Nasdaq listing :-
“ On top of all these fundamental triggers, a clear valuation trigger is the listing on NASDAQ USA before November this year. Analyzing peers in the US, there is a clear valuation discount for MaxCyte, which we think will close once on the NASDAQ.”

Also note today’s after hours RNS.
The rare beast that is a placing raising £40m at a PREMIUM to current SP.
That tells you that Institutional Investors want these shares and the only way to get them was to approach the company and offer to pay over the odds for a stake.
It also tells us that when Nasdaq listing does come it should be very well supported.

And from that RNS :-
“....... we continue to focus on accelerating revenue growth in 2021 and beyond, and marks a further important step towards our goal to dual-list on Nasdaq in 2021."

Having initially dismissed this article as just LFTs and not about us, I’m glad read it all. Here is the key line near the end. :-
“The Government is handling the cost and sourcing of tests for companies in its pilot until the end of March. Novacyt is one of the largest providers.”

Yep, it’s all that DHSC contract now. Price action today is fairly irrelevant in the longer scheme. Just some fun for the traders.
For shareholders, it’s wether this DHSC contract comes in and if so see where the SP is then. I’m still of the opinion they left the Update Ann as late as possible because they hoped to add in more news. I don’t think we’ll have long to wait though.
The lack of clarity in the Outlook was poor, but then again that can all depend on wether they drop a big contract next month.

No analyst briefings. Anyone seen a broker update?
Again what’s the point of a broker forecast today if there might be a single contract that’s bigger than the whole of last years revenues about to drop.

My advice. Unless you really really need the cash today, I’d sit tight and see what materialises.

The last, near as damn uninterrupted, meteoric rise lasted 6 weeks. We are only 2 weeks into this one. Long way to go yet and I believe GM has the fuel to keep it going.

I would say it’s a precursor to some corporate action. Be it a placing or a Nasdaq listing. Stifel should be able to attract US investors quite easily. A good raise from a position of strength should enable them to go full steam with product launch once FDA approval granted.

Yes he’s just a filtered green box for me.
His behaviour is strange really. I can’t imagine in real life, someone telling you in the bar to sell your shares, you ignore his advice, make a fortune and yet every week he keeps coming back and telling you what a bad investment it is.
Damn now I’m longing for the chance to go to a bar again!

Only profit,

As others have said, if you don’t already have an ISA, I strongly urge you to switch your shares into one asap. Ask your broker for a bed &isa.
Also a profit is not a profit until you sell. Likewise a loss. So make sure you crystallise these profits /losses to take advantage of CGT allowance.
Yes the losses will offset the profits. So as it stands there would be no CGT to pay.
Even with no CGT to pay you should still submit to HMRC as any unused CGT allowance can be carried forward to next year.

These are only my understandings and should not be taken as 100% correct. I would suggest you seek the advise of a professional accountant. They could save you far more than their fees cost.

BH2, yes I agree, that lack of info and under valuation presents opportunities to profit. However, my holding here is already overweight and there comes a point when the SP needs to attain fair value (not to mention overvalued ) to take advantage.

neilrich,

I am aware it is a Trading Update, I quite clearly state that in the opening line.

You ask why would they have an analyst Q&A?
Well to answer a lot of questions that I’m sure a lot of analysts will have.
But you seem to suggest it’s not the done thing. Then take a look at Maxcyte(MXCT) They announced a Trading Update last Wednesday (FY results will be April) and they held a Q&A.

“Conference call and webcast today

A conference call and webcast with Q&A for analysts hosted by CEO Doug Doerfler and CFO Amanda Murphy will be held at 1 p.m. GMT today, Wednesday, 20 January 2021. “

Following which we saw Buys of £6m and £3m that day. Don’t underestimate the power of a good analyst Q&A.

I personally don’t recall looking forward to a Trading Update as much as this weeks. It will make stunning reading and congratulations must go to GM and all the workers for the tremendous efforts they have put in this last year. The company has been totally transformed.
I’ve no idea what the revenue figs will be, but even at a figure I might be disappointed with, it’s going to be a 2000% increase on 2019. They’ve led the world in testing. First to develop a test and continually innovating to provide faster, simpler tests. Expanded manufacturing, created new jobs, cleared debt, acquired new business. And most importantly helped to save lives Quite remarkable from where they were.

And of course this has translated into a stunning SP performance. Top of the pile by a long way in share gainers for 2020, you can bet analysts and fund managers will be looking closely at these results. I presume there will be an analysts Q & A after. GM must feel like a football manager going into a press conference after his team has just won the World Cup. Congratulations all round.

However there is one thing that needs to be addressed. For despite stellar rise, it is frustrating that we still are valued on a par with our peers.
For me Novacyt needs to get away from being seen, wrongly, as the penny share punters darling and demonstrate they are a long term business with a clear strategy. GM has to provide better guidance to likely future revenues. If there is one thing the market doesn’t like it is uncertainty.

There has been little volume behind the SP rise this last 2 weeks. And tbh, if I were a fund manager, I wouldn’t be buying until results are out.But if GM can show the house broker forecasts are not pie in the sky, I think we could see some serious buying and SP rerate this next month. Add in the possibility of a new/ extended DHSC contract, US news, maybe even an acquisition....... Well who knows.

LittleWing.
From the TU on Wed.

“MaxCyte remains on schedule to pursue a Nasdaq dual listing in 2021”

I’m not sure what you’re expecting anyone to add to that.

Just had 6 successive days of rises. Needs to take a bit of heat off with a down day before resuming climb.

Agree HarChris. I can’t see the problem with discussing a popular investment strategy of top slicing on an investment BB.
I find it far more relevant than posts in which the author feels the need to invoke the spirit of Citizen Smith.

SP reactions on the day of results can very often leave investors bemused. Very good results can see a share fall, particularly if the market was expecting stunning results. Also remember a lot of traders will be buying this week in anticipation. The6 will sell on results day with no matter how good things look.

So how has Ncyt SP reacted recently to news?

16/9 SP was 370p.
17/9 Stunning H1 figs released. SP closed at 377.5p
However, with delayed reaction, by 28/9 SP was up to 467.5p
Then 29/9. Jaw dropping DHSC minimum £150m announced. SP closes at 532.5p, but 2 days later still only 530p.
Then again 11 days later on 12/10, SP risen to 844p.

Past performance is no guarantee of a repeat of course, but for those looking to top slice , waiting 10-14 days off the back of good news has proved to be successful.

No advice intended.

Kaeron, yes but 10:1 was only an example. If you prefer 3:1 split would meet your criteria. I thought market cap was more of a factor than actual SP when insts buy.

The £150m DHSC contract was announced to market 29th September to cover 14weeks. It’s unclear when it commenced, but I’ve assumed at least 90% of it would be shown as sales for this year, but who knows.

Another option to help with liquidity would be a share split. For instance a 10:1 split at current SP would give current holders ten x current holding, SP would rerate to 104.6p and would have 770m shares available to trade.

Hartlebury, forgot to say, I agree that a placing with institutions to fund a major acquisition would be welcome.

Hi Hartlebury.

I just feel we needs to get away from the sense of being a punters favourite. It was an absolute nonsense last year when we had Mandy scrambling around to get investors to back agm resolutions because so many made up a tiny percentage. In fairness that picture will have improved. But rightly or wrongly, I’d like fund managers to look at Ncyt and rather than just read it’s risen 10000% or whatever, look at it and see a glorious future and worthy of investment at £17 etc.
I guess I’m looking for exit points which are easier to hit with a steady rising SP rather than an SP that swings wildly because shorters/rampers/MMS know there are so many inexperienced investors here who will panic sell and buy.

By comparison look at say MXCT which has lovely rising chart, a compelling investment case, but has near zero interest from punters as there is a strong institutional shareholder base.

Bloody hell it’s gone like Piccadilly Circus in here!!
I was only commenting elsewhere this week how only 6 posts hon here since July when SP was only 217p. Some boards will have racked up 100k + posts in that time, with little quality.
As Scooby says this is not for the herd.

I strongly advise having a re read of the Nov presentation to whet the appetite.

https://otp.investis.com/Utilities/PDFDownload.aspx?Newsid=1427136